Pharmaceuticals 8 February 2026

Hims & Hers stock steadies premarket after Novo Nordisk patent suit jolts weight-loss push

Hims & Hers Health stock edged 0.1% higher to $17.25 ahead of the open Wednesday, recovering a sliver after tumbling 10.8% Tuesday and sinking 16% the session before.

11 February 2026

NYSE:HIMS·NYSE:NVO·Pharmaceuticals·Stock Market

Phio Pharmaceuticals (PHIO) stock rises premarket as new PH-762 skin cancer data keeps traders circling

Shares of Phio Pharmaceuticals Corp jumped 9.8% to $1.23 ahead of the bell Wednesday, buoyed by new safety and response data for its main skin-cancer program. On Tuesday, the stock settled at $1.12, up 24.4%.

11 February 2026

NASDAQ:PHIO·Pharmaceuticals·Stock Market

AbbVie stock price rises as analysts reset targets and Wall Street waits on delayed jobs data

AbbVie Inc climbed 0.7% to $224.83 in early afternoon trading Tuesday, sticking near its session peak. Shares moved in a narrow band, fluctuating between $223.00 and $225.78.

10 February 2026

NYSE:ABBV·Pharmaceuticals·Stock Market

Merck stock price slips after insider sale filings; what MRK investors are watching next

Merck & Co fell 0.5% to $117.01 on Tuesday, slipping further as the market processed new insider trading filings. Shares swung from $116.10 up to $118.14.

10 February 2026

NYSE:MRK·Pharmaceuticals·Stock Market

Johnson & Johnson stock price today: JNJ flat as March conference talks and insider filing draw focus

Johnson & Johnson stock hovered near $238.70 in late morning Tuesday, showing little movement as investors took in a newly posted conference schedule and fresh insider transaction filings. Shares have traded between $237.89 and $240.52 during the session.

10 February 2026

NYSE:JNJ·Pharmaceuticals·Stock Market

Hims & Hers stock price slides again as Novo Nordisk lawsuit tightens the screws on Wegovy copies

Hims & Hers Health shares slipped 5.6% to $18.25 on Tuesday. Investors showed caution following Novo Nordisk’s patent suit and ongoing U.S. attention on compounded weight-loss medications.

10 February 2026

NYSE:HIMS·NYSE:NVO·Pharmaceuticals·Stock Market

Eli Lilly stock price dips as $2.4 billion Orna deal and China pact grab attention

Eli Lilly and Company slipped 0.9% to $1,035.54 by 10:46 a.m. EST on Tuesday, giving back its early gains as the market reacted to fresh pipeline deals. Shares changed hands in a range from $1,032.21 to $1,054.31.

10 February 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Hims & Hers stock drops again premarket as $49 weight-loss pill reversal fuels legal, FDA scrutiny

Shares of Hims & Hers Health, Inc. dropped another 4.2% to $18.52 in Tuesday’s premarket, piling onto Monday’s sharp 16.0% slide that left the stock at $19.33 by the close.

10 February 2026

NASDAQ:HIMS·NYSE:NVO·Pharmaceuticals·Stock Market

China’s Arexvy review puts GSK stock back in focus before London trade

GSK plc shares are set to trade with new vaccine developments on the radar. The company reported that China’s Center for Drug Evaluation has taken up its application for Arexvy, the RSV shot designed for people 60 and up. GSK noted that, should approval come through, Arexvy would mark the first vaccine in China targeting RSV-linked lower respiratory tract disease in that demographic.

10 February 2026

LSE:GSK.L·NYSE:GSK·Pharmaceuticals·Stock Market

CSL shares slide as CEO Paul McKenzie retires, Gordon Naylor named interim ahead of results

CSL announced Tuesday that Chief Executive Paul McKenzie is stepping down, with Gordon Naylor stepping in as interim CEO and managing director beginning Feb. 11. McKenzie, who came aboard as chief operating officer in 2019, moved up to the CEO post in March 2023. During his tenure, CSL rolled out new treatments, including Hemgenix, its gene therapy for haemophilia B. Naylor, previously finance chief and head of the Seqirus vaccines division, took a board seat in December.

10 February 2026

ASX:CSL.AX·Pharmaceuticals·Stock Market

CSL CEO Paul McKenzie retires ahead of results, sending shares lower as Gordon Naylor steps in

CSL announced Tuesday that chief executive and managing director Paul McKenzie is stepping down. Gordon Naylor, a veteran executive at the company, will assume the interim CEO role starting Feb. 11.

10 February 2026

ASX:CSL·Pharmaceuticals·Stock Market

Hims & Hers stock sinks after $49 Wegovy copycat U-turn and Novo Nordisk lawsuit

Shares of Hims & Hers Health tumbled roughly 16%, landing at $19.33 in after-hours trading Monday, after the company scrapped its $49 compounded semaglutide pill and got hit with a patent suit from Novo Nordisk over the weight-loss treatment. Earlier, the stock touched $16.44 before trimming some of those declines.

10 February 2026

NYSE:HIMS·NYSE:NVO·Pharmaceuticals·Stock Market

Arrowhead Pharmaceuticals stock swings as S&P MidCap 400 move lands and Goldman flags 2026 catalysts (ARWR)

Arrowhead Pharmaceuticals slipped roughly 0.7% to $64.10 Monday afternoon, following a session that saw the stock range from $61.48 up to $66.17.

9 February 2026

NASDAQ:ARWR·Pharmaceuticals·Stock Market

Merck stock drops nearly 4%: why MRK is lagging the market today

Merck & Co slipped 3.9% to $117.16 by the afternoon, trailing a market that managed slight gains. The S&P 500 and Nasdaq edged up, but health care stocks struggled.

9 February 2026

NYSE:MRK·Pharmaceuticals·Stock Market

Novo Nordisk stock jumps 8% as Hims drops $49 semaglutide pill plan

Novo Nordisk climbed 8.3% to 320 Danish crowns in Copenhagen by 10:50 a.m. local time, after Hims & Hers scrapped plans for a $49 weight-loss pill made with compounded semaglutide—the same compound found in Novo’s Wegovy and Ozempic.

9 February 2026

CSE:NOVOB.CO·NASDAQ:HIMS·NYSE:LLY·Pharmaceuticals·Stock Market

GSK share price hovers near a 52-week high as COPD approval, U.S. drug discounts come into view

GSK edged up roughly 0.6% in early Monday action in London, with the stock hovering close to its 52-week peak. Shares hit 2,214 pence before settling at 2,211 by 0812 GMT.

9 February 2026

LSE:GSK·Pharmaceuticals·Stock Market

Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk A/S Class B starts the week with less pressure from copycat concerns, after Hims & Hers said it’s pulling its $49 compounded version of Novo’s Wegovy weight-loss pill. Novo, Hims & Hers, and Eli Lilly are also sinking serious money into Super Bowl ads, all trying to catch more cash-paying U.S. customers.

8 February 2026

CSE:NOVOB.CO·Health News·Pharmaceuticals·Stock Market

Novartis share price sits near a 52-week high after San Diego research build — what investors watch next

Novartis closed out Friday’s session at 119.96 Swiss francs, up 0.57%, after hitting a 52-week high of 120.64 earlier in the day. Shares next trade in Zurich on Monday.

8 February 2026

NYSE:NVS·Pharmaceuticals·Stock Market

Healthcare stocks set up for Monday: Hims drops $49 Wegovy copycat as FDA targets compounded GLP-1s

Hims & Hers announced Saturday it’s discontinuing access to its compounded semaglutide pill—previously sold at $49 a month—after U.S. regulators threatened enforcement on off-brand weight-loss treatments. Shares in Hims dropped 15.9% Friday, closing at $19.36. https://www.reuters.com/legal/litigation/hims-hers-stop-offering-compounded-semaglutide-pill-after-fda-crackdown-2026-02-07/ https://finance.yahoo.com/quote/HIMS/history/

8 February 2026

NASDAQ:HIMS·Pharmaceuticals·Stock Market

Merck stock is inches from a 52-week high — and an insider just sold shares

Merck & Co, Inc. finished Friday’s session up 1.82% at $121.93, putting the stock less than half a percent under its 52-week high as U.S. equities broadly rallied. While Pfizer and Eli Lilly posted bigger moves, Merck outperformed Johnson & Johnson. Trading volume landed at roughly 13 million shares, trailing the 50-day average, MarketWatch data shows.

8 February 2026

NYSE:MRK·Pharmaceuticals·Stock Market

Pharmaceuticals 8 February 2026 - 11 February 2026